European Journal of Clinical and Experimental Medicine T.17, z. 1 (2019)

URI dla tej Kolekcjihttp://repozytorium.ur.edu.pl/handle/item/4512

Przeglądaj

Przeglądanie European Journal of Clinical and Experimental Medicine T.17, z. 1 (2019) według Autor "Bar, Piotr"

Wpisz kilka pierwszych liter i kliknij przycisk Przeglądaj
Aktualnie wyświetlane 1 - 2 z 2
  • Obrazek miniatury
    Pozycja
    Infliximab in therapy of inflammatory bowels diseases
    (Wydawnictwo Uniwersytetu Rzeszowskiego, 2019) Bar, Piotr; Galiniak, Sabina; Bartusik-Aebisher, Dorota; Filip, Rafał; Aebisher, David
    Introduction. Infliximab is a monoclonal antibody that acts against tumor necrosis factor TNF-α. The drug is used in the treatment of autoimmune diseases. Aim. This article reviewed the efficacy and safety of infliximab for the treatment in severe ulcerative colitis. This review included studies that evaluated the clinical use of infliximab. Material and methods. This meta-analysis was performed according to systematic literature search of three major bibliographic databases (Scopus, PubMed, and Cochran). Results. Infliximab has been approved by the US Food and Drug Administration (FDA) as a medicine to treat Leśniowski and Crohn’s disease, ulcerative colitis, psoriasis, psoriatic arthritis, ankylosing spondylitis, and rheumatoid arthritis. However, further trials are required to compare other parameters of efficacy such as the clinical response with infliximab. Conclusion. In patients suffering from Crohn’s disease or ulcerative colitis under infliximab maintenance therapy, sustained good trough levels are associated with: better response and remission rates, more mucosal healing and less loss of response.
  • Obrazek miniatury
    Pozycja
    Infliximab MRI relaxation time in solution
    (Wydawnictwo Uniwersytetu Rzeszowskiego, 2019) Bober, Zuzanna; Bar, Piotr; Pasternak, Grzegorz; Galiniak, Sabina; Bartusik-Aebisher, Dorota; Filip, Rafał; Aebisher, David
    Introduction. The use of Quantitative Magnetic Resonance Imaging to drug monitoring in vitro or in vivo can provides a powerful means to map the effects of drugs on tissue activity. Aim. The purpose of this study was to measure relaxation time of antibody phantom. For this purpose, infliximab sample was used. Material and methods. The selected methods to detect relaxation time of antibody was Magnetic Resonance Imaging technique. We detected spin-lattice (T1) relaxation time and discuss differences where compare to water. Results. The measurements of spin-lattice (T1) relaxation time showed significant differences. The results obtained in phantom indicate that we can use this result for measurements of relaxation time in vitro. Conclusion. Infliximab is approved for severe cases of rheumatoid arthritis, together with methotrexate, for pronounced psoriasis and psoriasis-arthritis, ankylosing spondylitis as well as for chronic inflammatory bowel disease. We conclude, that Quantitative Magnetic Resonance Imaging can be used to monitor drug effects.